Spinal Cord Stimulation

Midwest, USA

Short Summary

Minority shareholder in medical software company is poised to acquire it and merge with publicly traded spinal cord stimulation hardware company that had $48 million in sales revenue in 2018 and create new closed-loop spinal cord stimulation therapy


Investment Raised
Previous Rounds N/A
Stage Achieving Sales
Investor Role Any


  • Nevro, brought their technology to market quickly capturing 16% of market
  • Nevro is a 1 product company trading at $2.5 billion enterprise value
  • In 2018 Electrocore had an IPO with enterprise value of $450 million
  • In 2018 Axionics Modulation also executed an IPO at $425M w/o FDA approval
  • Saluda Medical raised $85M from competitors and will likely pursue an IPO
Please note: Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. This information has not been approved as a financial promotion, and you must carry out your own due diligence.

Ask a question

Got a question about this project?

Sign up to view the full pitch

It's free to discover the next big thing

Already have an account?

Similar Projects

12% raised

Vein-Eye CARRY

location_on North East, USA

Near-Infrared Imaging is on the cusp of causing a paradigm shift in medical imaging The Vein-Eye® CARRY provides real-time video of sub-dermal veins. This is necessary to detect the exact direction and depth of the vein for quick IV placement.

US$ 250,000


US$ 100

Min per Investor

0% raised

Altering Helmet Design

location_on Midwest, USA

The patent-pending helmet design provides unseen safety features to a helmet user. The design utilizes a layered design technique to reduce strike forces hindering energy transfer to the user.

US$ 300,000


US$ 5,000

Min per Investor

30% raised

Cannabinoid Biotechnology

location_on West, USA

Emerald Health Pharmaceuticals; a biotech company entering Phase 2 human studies with patented unique cannabinoid science & technology focused on diseases like multiple sclerosis and Parkinson's disease; 180+ yrs mgt-team experience; $16M raised.

US$ 10,000,000


US$ 5,000

Min per Investor

load one similar proposal